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Abstract
Despite the extensive viral quasispecies that develops in an individual during the course of HIV-1 
infection, transmission is typically established by a single donor viral variant. Recent studies now 
provide insight into the phenotypic properties influencing this selection process at transmission 
including the contribution of resistance to type I interferons.
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HIV-1 mucosal transmission is an inherently inefficient process with less than 1% of 
unprotected sexual exposures leading to clinical infection. A central hallmark of 
transmission is the appearance of a severe population bottleneck whereby, in 80% of sexual 
transmission cases, infection is established by a single genetic variant (1). As recently 
summarized by Joseph et al. (2), the mechanism for this bottleneck includes a complex 
interplay of various anatomical and physiological barriers coupled with host innate immune 
responses that limit early viral replication and dissemination. This raises the question of 
whether these bottlenecks represent a stochastic process, in which any reasonably fit virus 
can establish a new infection, or whether there are selective forces favoring particular 
genotypic and phenotypic properties. Delineating the viral traits that correlate with 
transmission could advance strategies aimed at preventing HIV-1 transmission. To date, 
numerous studies have identified an array of genetic signatures specific to transmitted/
founder (TF) viruses, including residues clustering near the Env glycoprotein’s CD4-binding 
site (1). More intriguingly, a recent study by Carlson et al. characterizing 137 linked 
transmission pairs determined that mucosal transmission selects for viruses with a more 
consensus-like sequence, a bias that is mitigated by genital ulcers and inflammation (3). 
Such studies suggest that broader underlying phenotypic determinants may be augmenting 
the selection of viruses at transmission.
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In a recent study, Iyer and colleagues identified several biological features linked to 
enhanced transmission fitness (4). Owing to the labor intensiveness of molecular cloning 
they implemented a limiting dilution virus isolation approach to generate single virion 
plasma-derived HIV-1 isolates from eight epidemiologically-linked transmission pairs. By 
conducting in vitro replication assays on 300 virus isolates from the plasma of matched 
donor and recipients they found that recipient founder isolates were three times more 
infectious, had a 1.4-fold higher ability to replicate and were more efficiently released from 
infected cells than corresponding non-transmitting donor viruses (4). Most prominently, they 
found that recipient isolates required 8-fold and 39-fold higher concentrations of IFNα2 and 
IFNβ respectively to achieve a 50 percent reduction in replication, thus demonstrating that 
founder viruses were uniformly resistant to type I interferons (IFN-I) which form part of the 
innate immune response against infection (4). In addition, pre-treatment of CD4+ T cells 
with IFNβ alone selected for donor isolates with a phenotype that mirrored that of founder 
viruses. This study is congruent with their prior report demonstrating that founder viruses 
exhibit greater infectivity, bind to dendritic cells more efficiently and are resistant to 
inhibition by IFNα2 when compared to viruses derived from chronic infections (5). Taken 
together, these studies suggest that there is selection during the HIV-1 transmission 
bottleneck for virus variants that are adept at evading host innate responses.
In contrast, similar studies by Deymier et al. (6) and Oberle et al. (7) failed to find any 
significant difference in IFNα resistance between TF and non-transmitted viruses. 
Differences in study designs could account for these discrepancies, including HIV-1 clade-
specific effects, utilization of plasma-derived versus archived virus in peripheral blood 
mononuclear cells (PBMC) or molecular clones versus cultured virus isolates, as well as 
quantitation of input virus by particles versus infectious units. Notably, each of these studies, 
including Iyer et al., utilized transmission pairs to enable direct comparison of recipient 
founder viruses to their contemporaneous donor non-transmitted viruses. This is important 
because the wide range of viral phenotypes otherwise observed between chronically infected 
subjects could obscure the identification of more subtle phenotypes (4, 6, 7). However, since 
IFNα resistance appears to decrease shortly after infection and increase again during late-
stage chronic infection (4, 8), donor differences in the length of time since infection could 
also influence these findings.
Questions also remain regarding the specific viral genes responsible for mediating resistance 
to IFNα. Foster et al. now provide strong evidence for interferon-induced transmembrane 
protein (IFITM) resistance as a major determinant of HIV-1 transmission fitness, and 
demonstrate that this resistance is conferred by env (8). Specifically, neutralizing antibody 
escape mutations that accumulated after transmission were associated with enhanced 
sensitivity to IFITM-mediated restriction, suggesting that escape from adaptive immunity 
may render the virus more susceptible to restriction mediated by the innate immune system 
at the time of transmission. This observation is consistent with the findings from Carlson et 
al., where polymorphisms associated with immune escape were selected against during 
transmission (3). Of note, this selection bias was observed in gag, pol, and nef, suggesting 
that viral genes outside of env may also be influencing transmission fitness. Although this 
selection for consensus-like genomes was hypothesized to reflect higher in vivo fitness, 
follow-up studies by Deymier et al. found no association with in vitro replication capacity 
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(RC) (6). The authors did, however, observe that in vitro RC largely determined growth in 
the presence of IFNα, highlighting a clear correlation between IFNα resistance and the 
inherent ability of the virus to replicate (6). A recent study by Sutherland et al. observed a 
similar association between the in vitro RC of MJ4/gag chimeric viruses and their resistance 
to protease inhibitors (PI), with high RC viruses exhibiting lower PI susceptibility than low 
RC viruses (9). Therefore, the inherent in vitro RC of a virus may be influencing ‘in vivo 
resistance’ to a number of external selection forces and thus will need to be carefully 
considered when exploring factors influencing transmission, as will the impact of utilizing 
highly activated CD4+ T cells to derive viral isolates and to assay RC.
In summary, the extreme selection bottleneck that occurs during transmission provides a 
unique opportunity to identify virological attributes critical to the successful early 
replication of HIV-1. Iyer et al. now identify that resistance to IFN-I may reflect a key 
component of this early immunological bottleneck. In line with these findings, recent work 
by Sandler et al. demonstrate that pre-challenge administration of IFN-α2a prevented 
systemic SIV infection and limited the number of TF viruses in rhesus macaques (10). As 
such, further in vivo studies may help to clarify the role of IFN resistance and refine our 
understanding of the selective forces mediating HIV-1 transmission.
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